Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
Therapy Name | BHV-1530 |
Synonyms | |
Therapy Description |
BHV-1530 (AMB302) is an antibody-drug conjugate (ADC) comprising an FGFR3 antibody linked to a topoisomerase I inhibitor with ligase-dependent conjugation, which potentially inhibits growth of tumors with FGFR fusions or overexpression (Cancer Res (2023) 83 (7_Supplement): 2634). |
Drug Name | Trade Name | Synonyms | Drug Classes | Drug Description |
---|---|---|---|---|
BHV-1530 | BHV1530|BHV 1530AMB302|AMB-302|AMB 302|GR 1017|GR-1017|GR1017 | FGFR3 Antibody 5 | BHV-1530 (AMB302) is an antibody-drug conjugate (ADC) comprising an FGFR3 antibody linked to a topoisomerase I inhibitor with ligase-dependent conjugation, which potentially inhibits growth of tumors with FGFR fusions or overexpression (Cancer Res (2023) 83 (7_Supplement): 2634). |
Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
---|
Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
---|---|---|---|---|---|---|
NCT06874335 | Phase I | BHV-1530 | A Phase 1 Study of BHV-1530 (AMB302) in Advanced Solid Tumors | Recruiting | USA | 0 |